blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3620522

EP3620522 - METHODS FOR TREATMENT OF ALPORT SYNDROME [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.05.2024
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  23.06.2023
FormerGrant of patent is intended
Status updated on  06.02.2023
FormerExamination is in progress
Status updated on  11.12.2020
FormerRequest for examination was made
Status updated on  18.09.2020
FormerThe application has been published
Status updated on  07.02.2020
Most recent event   Tooltip11.10.2024Lapse of the patent in a contracting state
New state(s): IE		published on 13.11.2024 [2024/46]
Applicant(s)For all designated states
Sanofi
54, rue La Boétie
75008 Paris / FR
[2020/11]
Inventor(s)01 / DUFFIELD, Jeremy
3545 John Hopkins Court
Suite 210
San Diego, CA 92121 / US
02 / BHAT, Balkrishen
3545 John Hopkins Court
Suite 210
San Diego, CA 92121 / US
03 / MACKENNA, Deidre
3545 John Hopkins Court
Suite 210
San Diego, CA 92121 / US
 [2023/10]
Former [2020/11]01 / DUFFIELD, Jeremy
3545 John Hopkins Court
Suite 210
San Diego, CA California 92121 / US
02 / BHAT, Balkrishen
3545 John Hopkins Court
Suite 210
San Diego, CA California 92121 / US
03 / MACKENNA, Deidre
3545 John Hopkins Court
Suite 210
San Diego, CA California 92121 / US
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2023/30]
Former [2020/11]Chapman, Desmond Mark
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date19188663.908.10.2013
[2020/11]
Priority number, dateUS201261711514P09.10.2012         Original published format: US 201261711514 P
US201361779137P13.03.2013         Original published format: US 201361779137 P
[2020/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3620522
Date:11.03.2020
Language:EN
[2020/11]
Type: B1 Patent specification 
No.:EP3620522
Date:26.07.2023
Language:EN
[2023/30]
Search report(s)(Supplementary) European search report - dispatched on:EP21.01.2020
ClassificationIPC:C12N15/113, A61K31/7125, A61P13/12
[2020/11]
CPC:
C12N15/113 (EP,KR,US); A61K48/00 (KR); A61K31/4015 (US);
A61K31/593 (US); A61K31/7088 (EP,KR,US); A61K45/06 (US);
A61P13/00 (EP); A61P13/12 (EP,KR); A61P3/00 (EP);
C12N2310/113 (EP,KR,US); C12N2310/141 (KR); C12N2310/313 (US);
C12N2310/315 (EP,US); C12N2310/321 (EP,US); C12N2310/3233 (EP,US) (-)
C-Set:
C12N2310/321, C12N2310/3527 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/43]
Former [2020/11]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA11.09.2020
ME11.09.2020
TitleGerman:VERFAHREN ZUR BEHANDLUNG DES ALPORTSYNDROMS[2020/11]
English:METHODS FOR TREATMENT OF ALPORT SYNDROME[2020/11]
French:PROCÉDÉS DE TRAITEMENT DU SYNDROME D'ALPORT[2020/11]
Examination procedure11.09.2020Amendment by applicant (claims and/or description)
11.09.2020Examination requested  [2020/43]
11.09.2020Date on which the examining division has become responsible
14.12.2020Despatch of a communication from the examining division (Time limit: M06)
24.06.2021Reply to a communication from the examining division
20.09.2021Despatch of a communication from the examining division (Time limit: M06)
22.03.2022Reply to a communication from the examining division
07.02.2023Communication of intention to grant the patent
19.06.2023Fee for grant paid
19.06.2023Fee for publishing/printing paid
19.06.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP13777458.4  / EP2906698
Opposition(s)29.04.2024No opposition filed within time limit [2024/27]
Fees paidRenewal fee
26.07.2019Renewal fee patent year 03
26.07.2019Renewal fee patent year 04
26.07.2019Renewal fee patent year 05
26.07.2019Renewal fee patent year 06
31.07.2019Renewal fee patent year 07
14.10.2020Renewal fee patent year 08
29.09.2021Renewal fee patent year 09
15.09.2022Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
MC26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SI26.07.2023
SK26.07.2023
SM26.07.2023
IE08.10.2023
LU08.10.2023
NO26.10.2023
GR27.10.2023
BE31.10.2023
CH31.10.2023
IS26.11.2023
PT27.11.2023
[2024/46]
Former [2024/36]AT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
MC26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SI26.07.2023
SK26.07.2023
SM26.07.2023
LU08.10.2023
NO26.10.2023
GR27.10.2023
BE31.10.2023
CH31.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/34]AT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
MC26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SK26.07.2023
SM26.07.2023
LU08.10.2023
NO26.10.2023
GR27.10.2023
CH31.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/30]AT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
MC26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SK26.07.2023
SM26.07.2023
LU08.10.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/28]AT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
MC26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SK26.07.2023
SM26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/23]AT26.07.2023
CZ26.07.2023
DK26.07.2023
EE26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SK26.07.2023
SM26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/22]AT26.07.2023
CZ26.07.2023
DK26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RO26.07.2023
RS26.07.2023
SE26.07.2023
SM26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/20]AT26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RS26.07.2023
SE26.07.2023
SM26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/10]AT26.07.2023
FI26.07.2023
HR26.07.2023
LT26.07.2023
LV26.07.2023
NL26.07.2023
PL26.07.2023
RS26.07.2023
SE26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
PT27.11.2023
Former [2024/09]AT26.07.2023
FI26.07.2023
LT26.07.2023
NL26.07.2023
SE26.07.2023
NO26.10.2023
GR27.10.2023
IS26.11.2023
Former [2024/08]LT26.07.2023
NL26.07.2023
NO26.10.2023
GR27.10.2023
Former [2024/05]NL26.07.2023
Documents cited:Search[A]WO2011126842  (REGULUS THERAPEUTICS INC [US], et al) [A] 1-15 * sequence 6 *;
 [E]WO2013163258  (REGULUS THERAPEUTICS INC [US], et al) [E] 1-15* claims 39,42 *;
 [A]  - DAMIEN NOONE ET AL, "An update on the pathomechanisms and future therapies of Alport syndrome", PEDIATRIC NEPHROLOGY, (20120818), vol. 28, no. 7, doi:10.1007/s00467-012-2272-z, ISSN 0931-041X, pages 1025 - 1036, XP055094834 [A] 1-15 * page 1029 - page 1033 *

DOI:   http://dx.doi.org/10.1007/s00467-012-2272-z
 [A]  - X. ZHONG ET AL, "Smad3-Mediated Upregulation of miR-21 Promotes Renal Fibrosis", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (20110831), vol. 22, no. 9, doi:10.1681/ASN.2010111168, ISSN 1046-6673, pages 1668 - 1681, XP055094890 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1681/ASN.2010111168
 [A]  - JIN CHEN ET AL, "Relation between MicroRNA Expression in Peritoneal Dialysis Effluent and Peritoneal Transport Characteristics", DISEASE MARKERS, (201204), vol. 33, no. 1, doi:10.3233/DMA-2012-0901, ISSN 0278-0240, pages 35 - 42, XP055094926 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1155/2012/737169
 [A]  - CHEUK-CHUN SZETO ET AL, "Micro-RNA Expression in the Urinary Sediment of Patients with Chronic Kidney Diseases", DISEASE MARKERS, (20120928), vol. 33, no. 3, doi:10.3233/DMA-2012-0914, ISSN 0278-0240, pages 137 - 144, XP055094930 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1155/2012/842764
 [A]  - DOMINIC COSGROVE, "Glomerular pathology in Alport syndrome: a molecular perspective", PEDIATRIC NEPHROLOGY, (20110401), vol. 27, no. 6, doi:10.1007/s00467-011-1868-z, ISSN 0931-041X, pages 885 - 890, XP055094836 [A] 1-15 * page 887 - page 888 *

DOI:   http://dx.doi.org/10.1007/s00467-011-1868-z
 [A]  - OLIVER GROSS ET AL, "Treatment of Alport syndrome: beyond animal models", KIDNEY INTERNATIONAL, (20090617), vol. 76, no. 6, doi:10.1038/ki.2009.223, ISSN 0085-2538, pages 599 - 603, XP055094837 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/ki.2009.223
 [A]  - SANJEEV AKKINA ET AL, "MicroRNAs in kidney function and disease", TRANSLATIONAL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 157, no. 4, doi:10.1016/J.TRSL.2011.01.011, ISSN 1931-5244, (20110203), pages 236 - 240, (20110125), XP028368085 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.trsl.2011.01.011
 [A]  - SAAL SAMUEL ET AL, "MicroRNAs and the kidney: coming of age", CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, RAPID SCIENCE, LONDON, GB, (20090701), vol. 18, no. 4, doi:10.1097/MNH.0B013E32832C9DA2, ISSN 1062-4813, pages 317 - 323, XP008146126 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1097/MNH.0b013e32832c9da2
by applicantWO2008042973
    - AKINC et al., Nature Biotechnology, (20080501), vol. 26, pages 561 - 569
    - NOGRADY, Medicinal Chemistry A Biochemical Approach, Oxford University Press, (19850000), pages 388 - 392
    - KASHTAN, Nephrol. Dial. Transplant, (20020000), vol. 17, pages 1359 - 1361
    - CHAU et al., Sci Transl Med., (20120000), page 121ra18
    - MASARJIAN et al., Oligonucleotides, (20040000), vol. 14, pages 299 - 310
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.